Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham Edgbaston
InventorsJay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
Life of this patent
Estimating the term…
Abstract
β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.
Claims16
A composition comprising a β-mannosylceramide (β-ManCer) or salt or solvate thereof in a pharmaceutically acceptable carrier, wherein the β-ManCer consists of a β-mannosyl moiety linked to a ceramide moiety, the ceramide moiety consisting of:
- a) a sphingosine moiety linked to
- b) a fatty acid moiety comprising a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from about 8 to about 49 carbon atoms, wherein the composition further comprises a therapeutically effective amount of one or more chemotherapeutic agents.
Dependencies are inferred from the claim text.